Lucem Health announces new initiative to accelerate early detection of Type 1 Diabetes (T1D)

Pilot program, with support from Sanofi, aims to accelerate identification of presymptomatic, early-stage T1D using cutting-edge AI and readily available EHR data, with the goal of improving clinical outcomes through earlier diagnosis and intervention.

DAVIDSON, N.C., Sept. 9, 2025 /PRNewswire/ -- Lucem Health, a pioneer in AI-powered early disease detection, today announced the launch of a new program designed to accelerate the identification of individuals at risk for presymptomatic Type 1 Diabetes (T1D). This initiative expands Lucem Health's growing portfolio of AI-powered early detection solutions focused on accelerating disease detection, improving care delivery and enhancing patient outcomes

Reveal for T1D, the company's latest offering, leverages widely available electronic health record (EHR) data and cutting-edge AI to surface at-risk patients earlier – before symptoms emerge. This enables care teams to efficiently identify, engage, screen, and diagnose patients at risk for presymptomatic Type 1 Diabetes. Reveal for T1D operates seamlessly within existing clinical and technical workflows, streamlining both deployment and adoption for healthcare provider organizations.

"At Lucem Health, we are focused on shifting the timeline of diagnosis—from reactive to proactive," said Sean Cassidy, CEO of Lucem Health. "Reveal for T1D empowers providers to find patients earlier - when interventions are more effective, care is more coordinated, and outcomes are dramatically improved."

As part of its commitment to advancing autoimmune disease detection, Sanofi is providing support to this effort, helping raise awareness of the importance of earlier disease detection and intervention.

Type 1 Diabetes, a chronic condition where the body's immune system mistakenly attacks and destroys insulin-producing cells in the pancreas, can be confirmed with a simple blood test that detects islet autoantibodies. This technology, although available for years, is still underutilized for widespread screening. Early identification during Stage 1 or Stage 2—before symptoms emerge—offers significant clinical advantages. These include preventing life-threatening diabetic ketoacidosis (DKA), reducing healthcare costs, improving long-term glycemic control, enabling enrollment in clinical trials, and providing access to emerging therapies that may delay or prevent progression to Stage 3. Despite these benefits, 85–90% of individuals with Type 1 diabetes are still diagnosed at Stage 3, often after acute presentations such as DKA. Increasing awareness, expanding education, and promoting early screening can drive earlier interventions, better health outcomes, and a more proactive healthcare system that supports individuals, families, and the broader medical community.

This initiative reflects our commitment to equipping providers with tools that support earlier decision-making and improve patient care. To advance this commitment, Reveal for T1D is being made available to pilot health systems as part of a risk-free, introductory program, which includes full deployment support and customer success resources to accelerate impact.

"Reveal for T1D reflects Lucem's broader mission to equip health systems with AI that works—practically, responsibly, and at scale," said Holly Taylor, General Manager of Partnerships at Lucem Health. We are excited to support providers who are embracing new technologies to improve clinical outcomes and the promise of precision medicine."

Health Systems: To learn more or inquire about joining the pilot program, contact [email protected]

Patients and Families: Ask your doctor about islet autoantibody testing.

About Lucem Health

Lucem Health helps healthcare providers accelerate disease detection and treatment using practical, responsible AI, so they can improve patients' lives and increase the clinical and financial yield from today's scarce care delivery resources. We envision a world in which clinicians detect problems before they become life-threatening, and patients get world-class care, everywhere. Learn more at www.lucemhealth.com.

Media Contact:
Concetta Rasiarmos (Amendola Communications for Lucem Health)
630.740.3152
[email protected]

SOURCE Lucem Health